Mollaret and others1 employed Lygranum C. F. as an antigen against serums taken at various stages of cat scratch disease from 43 patients with clinically and skin test—proved disease and found a low complement-fixing titer in 20 (46.5%) (see table). They did not state the ages of their patients, nor did they record the results of tests on serums from any comparable group of normal individuals. They did, however, report finding an increased titer in serum from two patients in second bleedings. Serums drawn from each three to four weeks after the glands enlarged were negative but gave titers of 1:10 and 1:80 some weeks later. These authors deemed positive findings to have some diagnostic significance in cat scratch disease and to indicate that the disease belonged to the psittacosis-lymphogranuloma group of diseases. Lygranum C. F. is a commercial antigen prepared from venereal lymphogranuloma virus. The antigen gives
Armstrong C, Daniels WB, MacMurray FG, Turner HC. COMPLEMENT FIXATION IN CAT SCRATCH DISEASE EMPLOYING LYGRANUM C. F. AS ANTIGEN. JAMA. 1956;161(2):149–150. doi:10.1001/jama.1956.62970020006006b
Browse and subscribe to JAMA Network podcasts!
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: